Participant Perceptions in a Long-term Clinical Trial of Autosomal Dominant Polycystic Kidney Disease

[1]  M. Zeitlinger,et al.  Perception of clinical research among patients and healthy volunteers of clinical trials , 2022, European Journal of Clinical Pharmacology.

[2]  V. Perkovic,et al.  Platform Clinical Trials Within Nephrology-Interpreting the Evidence. , 2022, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[3]  R. Jacques,et al.  Recruitment, consent and retention of participants in randomised controlled trials: a review of trials published in the National Institute for Health Research (NIHR) Journals Library (1997–2020) , 2022, BMJ Open.

[4]  David W. Johnson,et al.  Prescribed Water Intake in Autosomal Dominant Polycystic Kidney Disease , 2021, NEJM Evidence.

[5]  S. Straus,et al.  Parent engagement in co-design of clinical trials: the PARENT trial , 2021, Trials.

[6]  Gopala K. Rangan,et al.  Current and emerging treatment options to prevent renal failure due to autosomal dominant polycystic kidney disease , 2020 .

[7]  David W. Johnson,et al.  Recruitment and retention in clinical trials in chronic kidney disease: report from national workshops with patients, caregivers and health professionals. , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[8]  David W. Johnson,et al.  Identifying patient‐important outcomes in polycystic kidney disease: An international nominal group technique study , 2019, Nephrology.

[9]  S. Treweek,et al.  Strategies to improve recruitment to randomised trials. , 2018, The Cochrane database of systematic reviews.

[10]  C. Gamble,et al.  ‘Recruitment, recruitment, recruitment’ – the need for more focus on retention: a qualitative study of five trials , 2018, Trials.

[11]  David W. Johnson,et al.  Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD) , 2018, BMJ Open.

[12]  C. Chesla,et al.  Understanding barriers to medication, dietary, and lifestyle treatments prescribed in polycystic kidney disease , 2017, BMC Nephrology.

[13]  L. Martin,et al.  How much do clinical trials cost? , 2017, Nature Reviews Drug Discovery.

[14]  D. Needham,et al.  Participant retention practices in longitudinal clinical research studies with high retention rates , 2017, BMC Medical Research Methodology.

[15]  Adrian Bauman,et al.  Process evaluation of TXT2BFiT: a multi-component mHealth randomised controlled trial to prevent weight gain in young adults , 2016, International Journal of Behavioral Nutrition and Physical Activity.

[16]  Naihua Duan,et al.  Purposeful Sampling for Qualitative Data Collection and Analysis in Mixed Method Implementation Research , 2015, Administration and Policy in Mental Health and Mental Health Services Research.

[17]  B. Coller,et al.  Development of a Research Participants’ Perception Survey to Improve Clinical Research , 2012, Clinical and translational science.

[18]  Helvi Kyngäs,et al.  The qualitative content analysis process. , 2008, Journal of advanced nursing.

[19]  P. Sainsbury,et al.  Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. , 2007, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[20]  M. Rotheram-Borus,et al.  Successful recruitment and retention of participants in longitudinal behavioral research. , 2003, AIDS education and prevention : official publication of the International Society for AIDS Education.

[21]  R. Prescott,et al.  Barriers to participation in randomised controlled trials: a systematic review. , 1999, Journal of clinical epidemiology.